Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Vor Biopharma Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-12-31
Exact text from the filing
Proposal 3 - Ratification of Selection of Independent Registered Public Accounting Firm The Stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the following votes: For Against Abstain 33,877,004 133,499 1,501
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Vor Biopharma Inc. shareholders approved Election of Two Class II Directors Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D..
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Proposal 1 - Election of Two Class II Directors Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D. were each elected to serve as a member of the Board until the 2029 Annual Meeting of Stockholders and until his successor is duly elected or qualified, or, if sooner, until the director’s death, resignation or removal, by the following votes: Nominee For Withheld Broker Non-Votes Andrew Levin, M.D., Ph.D. 25,797,081 120,813 7,094,110 Fouad Namouni, M.D. 22,825938 4,091956 7,094,110
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Vor Biopharma Inc. shareholders approved Amendment and Restatement of the Company's Amended and Restated 2021 Equity Incentive Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
Proposal 2 - Amendment and Restatement of the Company's Amended and Restated 2021 Equity Incentive Plan The Stockholders approved the Amended 2021 Plan by the following votes. For Against Abstain Broker Non-Votes 20,146,430 6,767,428 4,036 7,094,110
View on SEC.gov